If you are a Shareholder, demand more. If you are an analyst, ask questions about this, and if you are a potential investor, look elsewhere or expect massive loss.
You are being sold a Bill of goods. A good old fashion conn job. DSO is being touted on news outlets and social media platforms as the savior for Bayer. The reality is in the US and specifically in the Pharma segment, there is NO DSO, and the old cronies that have been in Pharma their entire careers, are forcing top-down decisions that make no sense and destroy culture. The very same leaders that have failed miserably at launching one of Bayer’s cornerstone products, Kerendia, are now attempting a hail Mary to elevate some internal metric, share of voice, in an attempt to salvage the disaster they created. There is absolutely no benefit to the customer with this in fact this will only lead to more confusion in the marketplace and another reason for prescribers to turn from Bayer. Moreover, this will lead to enormous dissatisfaction with the people who handle the customers in the non Kerendia product lines, and major decline in sales, as well as the culture at Bayer for those who stay.
At a time when Bayer needs to maximize revenue, these decisions will decimate sales with all Pharma products, not just Kerendia, and Bayer will lose the incredible talent that has salvaged what revenue we still produce. These decisions have created a massive distraction for all and a toxic culture.
If you are a Shareholder, demand more. If you are an analyst, ask questions about this, and if you are a potential investor, look elsewhere or expect massive loss.
You are being sold a Bill of goods. A good old fashion conn job. DSO is being touted on news outlets and social media platforms as the savior for Bayer. The reality is in the US and specifically in the Pharma segment, there is NO DSO, and the old cronies that have been in Pharma their entire careers, are forcing top-down decisions that make no sense and destroy culture. The very same leaders that have failed miserably at launching one of Bayer’s cornerstone products, Kerendia, are now attempting a hail Mary to elevate some internal metric, share of voice, in an attempt to salvage the disaster they created. There is absolutely no benefit to the customer with this in fact this will only lead to more confusion in the marketplace and another reason for prescribers to turn from Bayer. Moreover, this will lead to enormous dissatisfaction with the people who handle the customers in the non Kerendia product lines, and major decline in sales, as well as the culture at Bayer for those who stay.
At a time when Bayer needs to maximize revenue, these decisions will decimate sales with all Pharma products, not just Kerendia, and Bayer will lose the incredible talent that has salvaged what revenue we still produce. These decisions have created a massive distraction for all and a toxic culture.
If you are a Shareholder, demand more. If you are an analyst, ask questions about this, and if you are a potential investor, look elsewhere or expect massive loss.